QUANTRO will combine and exploit innovative technologies in the areas of functional-genetics and transcriptomics to generate an unprecedented cancer drug discovery pipeline transforming the precision and scope of cell-based compound screens.
QUANTRO Therapeutics GmbH is a privately funded research company that strives to discover and develop novel effective therapeutics that interfere with disease-causing transcriptional programs in cancer and other diseases.
Based on proprietary transcriptional signatures, QUANTRO will assemble a highly innovative drug-discovery pipeline that employs time-resolved RNA sequencing and comparative transcriptomics to identify drug candidates interfering with transcriptional regulators.
By introducing ‘transcriptional fingerprinting’ to drug discovery, QUANTRO intends to revamp the scope of pharmacologic interventions in a variety of cellular, target and disease contexts.
A prime focus will be the discovery and development of drug candidates blocking the activity of oncogenic transcription factors, a class of particularly promising therapeutic targets that has so far remained largely unamenable to pharmacological intervention.
Read more about Our Science
Spin-off of IMBA and IMP
QUANTRO Therapeutics GmbH was founded in Vienna, Austria, as a spin-off of the Research Institute of Molecular Pathology (IMP) and the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA). Both institutes are co-located at the Vienna BioCenter (VBC), in the heart of the vibrant Austrian capital.
As the company is established in the new Startup Labs Facility of the Vienna Business Agency, located at the Vienna BioCenter, QUANTRO will benefit from the collaborative spirit at one of the leading life-science locations in Europe.
Boehringer Ingelheim Venture Fund and Evotec are both minority shareholders and represent two of the World’s leading life science organizations with outstanding knowledge and expertise.
Boehringer Ingelheim Venture Fund (BIVF)
Operating as a separate legal entity, the Boehringer Ingelheim Corporate Venture Fund drives innovation through its strategic investments in early-stage science and technology. With an investment volume of 300 million EUR, the Venture Fund invests in biotech and start-up companies with innovative concepts and technologies that have the potential to provide ground-breaking therapeutic platforms.
The Venture Fund’s interest in young, mainly technology-oriented companies demonstrates its commitment to investigate new ideas and emerging science to create options for Boehringer Ingelheim to expand into novel therapeutic approaches and businesses in the fields of Oncology, Regenerative Medicine and Infectious Diseases.
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide with more than 3,000 employees providing the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women’s health. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.
Dr. Sebastian Kreuz
Boehringer Ingelheim Venture Fund
“The BIVF focuses on groundbreaking therapeutic approaches and technologies that have the potential to advance patient care in areas of high unmet medical need.”
“We are looking forward to support QUANTRO and its dedicated founders to apply time-resolved RNA sequencing in an industrialized setting with the aim to unlock transcription factors as a highly promising target class for drug discovery in oncology and other disease areas.”
Dr. Werner Lanthaler
Chief Executive Officer of Evotec
“QUANTRO is a very promising academic spin-off company with great potential to lead the way in mRNA sequencing based drug discovery. SLAM-SEQ in combination with other technologies as intended by QUANTRO is a potentially ground-breaking approach to address ‘undruggable’ drug targets.”
“Through our partnership and equity investment, we will further validate QUANTRO’s approach and hope to be able to open many new doors across a broad range of therapeutic modalities together in the future.”